Exact Sciences Co. (NASDAQ:EXAS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Exact Sciences Co. (NASDAQ:EXASGet Rating) have received a consensus rating of “Moderate Buy” from the fifteen ratings firms that are covering the firm, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $64.86.

A number of research analysts recently issued reports on the company. Robert W. Baird reduced their price target on Exact Sciences from $75.00 to $60.00 in a report on Friday, November 4th. BTIG Research reduced their price target on Exact Sciences from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Monday, November 7th. Credit Suisse Group assumed coverage on Exact Sciences in a report on Wednesday, August 24th. They set an “outperform” rating and a $55.00 price target on the stock. StockNews.com assumed coverage on Exact Sciences in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, Evercore ISI upped their target price on Exact Sciences to $65.00 in a report on Tuesday, August 9th.

Exact Sciences Stock Up 2.0 %

Shares of NASDAQ:EXAS opened at $43.09 on Friday. Exact Sciences has a 1 year low of $29.27 and a 1 year high of $90.39. The company has a market cap of $7.66 billion, a PE ratio of -10.51 and a beta of 1.31. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.47 and a quick ratio of 2.20. The stock’s 50-day moving average is $36.46 and its 200 day moving average is $41.36.

Insider Transactions at Exact Sciences

In related news, insider Everett Cunningham sold 16,872 shares of the company’s stock in a transaction that occurred on Wednesday, October 12th. The stock was sold at an average price of $31.37, for a total value of $529,274.64. Following the transaction, the insider now directly owns 18,654 shares of the company’s stock, valued at approximately $585,175.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Exact Sciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EXAS. Armistice Capital LLC bought a new position in Exact Sciences in the 3rd quarter valued at approximately $50,684,000. Capital World Investors raised its stake in Exact Sciences by 17.2% during the 1st quarter. Capital World Investors now owns 5,487,009 shares of the medical research company’s stock valued at $383,652,000 after buying an additional 804,159 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. raised its stake in Exact Sciences by 12.2% during the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 6,517,145 shares of the medical research company’s stock valued at $211,742,000 after buying an additional 709,540 shares during the last quarter. Vanguard Group Inc. raised its stake in Exact Sciences by 4.4% during the 3rd quarter. Vanguard Group Inc. now owns 16,676,611 shares of the medical research company’s stock valued at $541,823,000 after buying an additional 698,740 shares during the last quarter. Finally, ARK Investment Management LLC raised its stake in Exact Sciences by 4.5% during the 2nd quarter. ARK Investment Management LLC now owns 14,971,765 shares of the medical research company’s stock valued at $745,744,000 after buying an additional 647,803 shares during the last quarter. 90.95% of the stock is owned by institutional investors.

Exact Sciences Company Profile

(Get Rating)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services.

Featured Stories

Analyst Recommendations for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.